|
|
|
|
AstraZeneca International - pharmaceutical company, prescription drugs, medicine manufacturers
Skip to content Home Media Investors Careers Products Licensing Research Responsibility About us Contact us - - EMLA (Eutectic Mixture of Lidocaine and Prilocaine) EMLA (Eutectic Mixture of Lidocaine and Prilocaine) is a local anaesthetic for topical application, developed to anaesthetise intact skin.
EMLA is used to prevent pain associated with needle insertion, intravenous...
|
|
|
AstraZeneca International - pharmaceutical company, prescription drugs, medicine manufacturers
Skip to content Home Media Investors Careers Products Licensing Research Responsibility About us Contact us - - Neuroscience Health problems related to the function of the nervous system, including the brain, are a complex area of significant medical need that touches many people's lives.
Our range of neuroscience products includes world leading anaesthetics Diprivan and Xylocaine...
|
|
|
AstraZeneca Products - Drug information, prescription medicines, pharmaceuticals
Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - -Products - - Products Our skills and resources are concentrated on six important areas of healthcare - representing the majority of the worldwide burden of disease.
We...
|
|
|
EMLA (Eutectic Mixture of Lidocaine and Prilocaine) - AstraZeneca
Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - - Products - -Neuroscience - - EMLA (Eutectic Mixture of Lidocaine and Prilocaine) EMLA (Eutectic Mixture of Lidocaine and Prilocaine) is a local anaesthetic for topical...
|
|
|
AstraZeneca Products - Drug information, prescription medicines, pharmaceuticals
Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - -Products - - Products Our skills and resources are concentrated on six important areas of healthcare - representing the majority of the worldwide burden of disease.
We...
|
|
|
AstraZeneca Products - Drug information, prescription medicines, pharmaceuticals
Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - -Products - - Products Our skills and resources are concentrated on six important areas of healthcare - representing the majority of the worldwide burden of disease.
We...
|
|
|
AstraZeneca Products - Neuroscience - Schizophrenia, central nervous system, migraine treatments
Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - - Products - -Neuroscience - - Neuroscience Health problems related to the function of the central nervous system, including the brain, are a complex area of significant...
|
|
|
AstraZeneca Products - Drug information, prescription medicines, pharmaceuticals
Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - -Products - - Products Our skills and resources are concentrated on six important areas of healthcare - representing the majority of the worldwide burden of disease.
We...
|
|
|
Microsoft Word - RPSepicPOM
A Aciclovir 6 Acrivastine 6 Aluminium chloride 6 Aspirin 8, 46 Astemizole 5 Atropine Sulphate 9 Azelastine 8, B Beclomethasone Dipropionate 6, 47 Benzocaine 47 Benzoyl Peroxide 46 Budesonide 8 C Cadexomer- Iodine 8 Camphor 47 Carbenoxolone 6 Cetirizine 6,47 Cimetidine 6 Chloramphenicol 9 Clobetasone 9 Clotrimazole 6,8,46 Co- methiamol 29 D Dequalinium chloride 46 Dextranomer 5...
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
ACTHAR GEL, CORTICOTROPIN H.R.-50, HYDROCHLOROTHIAZIDE HABITROL, NICOTINE (OTC) HALCION, TRIAZOLAM HALDOL SOLUTAB, HALOPERIDOL HALDOL, HALOPERIDOL HALDOL, HALOPERIDOL DECANOATE HALDOL, HALOPERIDOL LACTATE HALDRONE, PARAMETHASONE ACETATE HALFAN, HALOFANTRINE HYDROCHLORIDE HALOG, HALCINONIDE HALOG-E, HALCINONIDE HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE HALOPERIDOL INTENSOL,...
|
|
|
1998 Warning Letters and Untitled Letters to Pharmaceutical Companies
Food and Drug Administration • Center for Drug Evaluation and Research Compliance Activities Search Warning Letters and Untitled Letters to Pharmaceutical Companies 1998 These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office
DDMAC 4/27 5/7 MUSE (alprostadil) urethral suppository Vivus DDMAC 4/1 4/9 Nicotrol Inhaler (nicotine)...
|
|
|
Prescription and Over-the-Counter Drug Product List: 8/2003
4 >D> AA + ORTHO MCNEIL PHARM 300MG;60MG N85055 004 AUG DISC >A> @ 300MG;60MG N85055 004 AUG DISC ACETAMINOPHEN; HYDROCODONE BITARTRATE SOLUTION; ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> AA + MALLINCKRODT 500MG/15ML;10MG/15ML N40508 001 AUG 29, 2003 AUG NEWA >D> MIKART 500MG/15ML;5MG/15ML N81226 001 OCT 27, 1992 AUG CTEC >A> AA 500MG/15ML;5MG/15ML N81226 001 OCT 27, 1992 AUG...
author: AUTHOR
|
|
|
Analgesia and Procedural Sedation
when combined with non-med adjuncts splints) SE – liver toxicity in alcholics or in overdose Local Agents EMLA Lidocaine 2.5%, Prilocaine 2.5% Most effective on face/scalp Requires 60 mins to obtain complete anesthesia AVOID mucosal contact (cases of toxicity/death) Not sterile LET Lidocaine 4%, epinephrine 0.1%, tetracaine 0.5% Largely replaced TAC Can...
author: KT Morgenstern
|
|
|
REGIONAL ANAESTHESIA
Laurie-Ann Baker Objectives: l Review of common local anesthetics (LA’s) – – – Mechanism of action Injection techniques Toxicity l l Defining regional anesthesia Commonly used peripheral nerve blocks Review of the handout Local Anesthetics: l Short Term Pain Relief By: – – – Infiltration or application of LA directly into the area to be anesthetized...
author: ADELE FEDORAK
|
|
|
Pain in neonates
Among the circumcised group, preoperative treatment with EMLA attenuated the pain response to vaccination l l The pain itself may not be consciously remembered but the painful experience does l Consequences of inadequate Analgesia during painful procedures in childen
Single dose does not cause Methemoglobinemia (Prilocaine side effect) EMLA l 4% Tetracaine cream ...
author: N. Ambalavanan MD
|
|
|
FDA Drug Approvals List April 2000
Approvable Original New Drug Applications Original Abbreviated New Drug Applications Original Abbreviated Application # 074657 Approval Date: 28-APR-00 Trade Name: TERAZOSIN HCL Dosage Form: TABLET Applicant: INVAMED INC Active Ingredient(s): TERAZOSIN HYDROCHLORIDE OTC/RX Status: RX Original Abbreviated Antibiotic Application# 065041 Approval Date: 28-APR-00 Trade Name: DOXYCYCLINE...
|
|
|
EFFICACY SUPPLEMENTS APPROVED IN CY 2000
EFFICACY SUPPLEMENTS APPROVED IN CY 2000 GENERIC NAME APPLICANT NDA NUMBER RECEIPT DATE APPROVAL DATE SUPP TYPE SUPP NUMBER PRIORITY REVIEW TOTAL APPROVAL TIME (MONTHS) INDICATION/DESCRIPTION IBUPROFEN WHITEHALL ROBINS 20-812 15-Jun-98 12-Jan-00 SE5 003 N 18.9 Provides for the use of Infants' Advil (ibuprofen oral suspension) Concentrated Oral Drops, 50 mg/1.25 mL for ages 6 months...
|
|
|
FDA Drug Approvals List- February 1998
Drug Approvals for February 1998 Definitions and Notes February 1998 Original New Drug Applications Original Application #: 050750 Approval Date: 24-FEB-98 Trade Name: ZOSYN Chemical Type: 3 Therapeutic Potential: S Dosage Form: INJECTABLE Applicant: LEDERLE PIPERACILLIN INC DIV AMERICAN CYANAMID CO Active Ingredient(s): PIPERACILLIN SODIUM; TAZOBACTAM SODIUM OTC/RX Status: RX...
|
|
|
FDA Drug Approvals List January 2000
- Drug Approvals for January 2000 Definitions and Notes Original New Drug Applications Original Application #: 020939 Approval Date: 28-JAN-00 Trade Name: DILTIAZEM HCL Chemical Type: 5 Therapeutic Potential: S Dosage Form: CAPSULE, EXTENDED RELEASE Applicant: BIOVAIL LABORATORIES INC Active Ingredient(s): DILTIAZEM HYDROCHLORIDE OTC/RX Status: RX Indication(s): Treatment of...
|
|
|
http://www.cancercare.on.ca/formulary/pdfmedicationinfo/Emla.pdf
For more information on this medication, please call your doctor or nurse, or the Cancer Centre Drug Information pharmacist. MEDICATION INFO SHEET EMLA CREAM (EMM- la) Other Names for this Medication: EMLA (Brand Name) Lidocaine- Prilocaine Eutectic Mixture (Generic Name) Appearance: White ...
|
|
|
http://www.cancercare.on.ca/formulary/pdfmedicationinfo/Emla.pdf page 1
For more information on this medication, please call your doctor or nurse, or the Cancer Centre Drug Information pharmacist. MEDICATION INFO SHEET EMLA CREAM (EMM- la) Other Names for this Medication: EMLA (Brand Name) Lidocaine- Prilocaine Eutectic Mixture (Generic Name) Appearance: White ...
|
|
|
http://www.fda.gov/cder/foi/label/2000/19941S11LBL.PDF
234.3 Prilocaine is chemically designated as propanamide, N-( 2- methyl- molecular structure phenyl)- 2-( propylamino), has an octanol: water partition ratio of 25 at pH 7.4, and has the following structure: C13H20N2O M
TABLE 1 Absorption of Lidocaine and Prilocaine from EMLA Cream: Normal Volunteers (N= 16) EMLA (g) Area (cm 2 ) Time on (hrs) Drug...
|
|
|
http://www.fda.gov/cder/foi/label/2000/19941S11LBL.PDF page 7
|
|
|
http://www.fda.gov/cder/foi/label/2000/19941S11LBL.PDF page 3
|
|
|
http://www.fda.gov/cder/foi/label/2000/19941S11LBL.PDF page 2
|
